Latest Cisplatin Stories

SEATTLE, Dec. 5, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported on interim results from a cooperative group sponsored Phase 2 clinical trial of brostallicin in combination with cisplatin for the treatment of women with metastatic triple-negative breast cancer that were presented at the San Antonio Breast Cancer Symposium (SABCS) held from December 4-8, 2012. The study enrolled women with confirmed measurable metastatic disease and triple...

Connie K. Ho for redOrbit.com – Your Universe Online A new study from scientists at the University of Southern California shows that a new drug could be used to help ovarian cancer patients who have not been receptive to drugs that are currently available and possibly reduce the drug dosage needed to be taken. In particular, the drug has been tested in a lab with ovarian cancer cells and on mice tumors. It is part of a group of cytotoxic agents, known as PACMA, that was discovered...

RIDGEFIELD, Conn., Sept. 28, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced new patient-reported health-related outcomes for its investigational oncology compound afatinib,* including lung cancer-related symptoms and quality of life (QoL). These data are secondary endpoints of LUX-Lung 3, a Phase III trial of afatinib (n=230) compared to chemotherapy (pemetrexed/cisplatin) (n=115) in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced...

Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports. The findings reveal a potential biomarker that can be used to predict how these patients will respond to chemotherapy, as well as the patients' overall prognosis, paving the way for personalized treatment...

Connie K. Ho for redOrbit.com - Your Universe Online Researchers at the Massachusetts Institute of Technology (MIT) recently revealed a new platinum compound that could eliminate cancer cells more effectively than cisplatin, a popular chemotherapy anticancer drug. Drugs that have platinum are the most widely used most powerful cancer drugs. On the downside, these agents have toxic side effects and the cancer cells can eventually become resistant; as such, the new discovery is exciting for...

Researchers at Brigham and Women's Hospital (BWH) are the first to report a new approach that integrates rational drug design with supramolecular nanochemistry in cancer treatment. Supramolecular chemistry is the development of complex chemical systems using molecular building blocks. The researchers utilized such methods to create nanoparticles that significantly enhanced antitumor activity with decreased toxicity in breast and ovarian cancer models. "This work is effectively moving...

A long-used anti-cancer drug could be a starting point to develop new treatments for the incurable nerve disease known as Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS), scientists are reporting. Their research showing how the drug prevents clumping of an enzyme linked to ALS appears in the Journal of the American Chemical Society. Lucia Banci, Ivano Bertini and colleagues explain that ALS causes a progressive loss of muscle control as the nerves that control body movements...

A new study by University of Kentucky researchers shows how light and strained ruthenium-based drugs may be more effective at fighting cancer cells and less toxic to healthy cells than a similar and widely used drug. Cisplatin is a common platinum-based cancer drug. But while cisplatin kills cancer cells, it also attacks healthy cells, causing debilitating side effects. Ruthenium is a rare transition metal also belonging to the platinum group of the periodic table, and the UK researchers...

INDIANAPOLIS, June 4, 2012 /PRNewswire/ -- Final results from PARAMOUNT, a Phase III study of ALIMTA(® )(pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated with ALIMTA continuation maintenance, according to data announced today by Eli Lilly and Company (NYSE: LLY). PARAMOUNT results will be presented on Monday, June 4, at the 48th Annual...

LUX-Lung 3 trial results highlighted at the official ASCO Press Conference: Afatinib* delays lung cancer progression compared to standard chemotherapy BURLINGTON, ON, June 4, 2012 /CNW/ - The LUX-Lung 3 Phase III results showed that lung cancer patients taking the novel compound afatinib*, an irreversible ErbB Family Blocker, as a first-line treatment, lived for almost one year before their disease progressed (progression-free survival (PFS) of 11.1 months) versus just over half...